Result of Annual General Meeting

Arix Bioscience PLC (ARIX) Result of Annual General Meeting 23-May-2023 / 16:30 GMT/BST Arix Bioscience plc Result of Annual General Meeting LONDON, 23 May 2023: Arix Bioscience plc (“Arix” or the “Company”) (LSE: ARIX), a transatlantic venture capital company focused on investing in breakthrough biotechnology companies, announces that at its Annual General Meeting (the "Meeting") duly convened and held today, all resolutions as set out on the notice of meeting were duly passed by way of a poll. Resolutions 1 to 11 were passed as ordinary resolutions. Resolutions 12 to 15 were passed as special resolutions. Full details of the poll results are set out below and will also be available on the Company's . No RESOLUTION VOTES FOR % VOTES AGAINST % TOTAL VOTES % of ISC VOTED VOTES WITHHELD 1 To receive the Directors' Report and the accounts of the Company for the year ended 31 December 2022 68,931,411 100.00% 3,441 0.00% 68,934,852 53.28% 8,440 2 To approve the Directors' Remuneration Report 61,073,950 89.25% 7,358,207 10.75% 68,432,157 52.89% 511,135 3 To re-elect Peregrine Moncreiffe as a Director 68,099,019 98.79% 834,821 1.21% 68,933,840 53.28% 9,452 4 To re-elect Maureen O'Connell as a Director 68,894,053 99.94% 42,077 0.06% 68,936,130 53.28% 7,162 5 To re-elect Isaac Kohlberg as a Director 68,900,656 99.98% 17,184 0.02% 68,917,840 53.26% 25,452 6 To re-elect Robert Lyne as a Director 68,902,689 99.95% 31,595 0.05% 68,934,284 53.28% 9,008 7 To elect Dr. Debra Barker as a Director 68,907,528 99.95% 32,248 0.05% 68,939,776 53.28% 3,516 8 To elect Andrew Smith as a Director 68,921,195 99.98% 13,089 0.02% 68,934,284 53.28% 9,008 9 To appoint BDO LLP as auditors of the Company 68,929,881 99.99% 7,445 0.01% 68,937,326 53.28% 5,966 10 To authorise the Audit and Risk Committee of the Company to fix the auditor's remuneration 68,934,245 100.00% 2,013 0.00% 68,936,258 53.28% 7,034 11 To authorise the Directors to allot shares 65,989,256 95.72% 2,950,520 4.28% 68,939,776 53.28% 3,516 12 Authority to disapply statutory pre‐ emption rights 62,199,252 90.23% 6,734.680 9.77% 68,933,932 53.28% 9,360 13 Additional authority to disapply statutory pre‐ emption rights 62,202,105 90.23% 6,731,827 9.77% 68,933,932 53.28% 9,360 14 To authorise the Company to purchase its own shares 68,921,128 99.98% 17,177 0.02% 68,938,305 53.28% 4,987 15 Authority to call a general meeting, other than an annual general meeting, on not less than 14 clear days' notice 68,145,351 98.85% 792,954 1.15% 68,938,305 53.28% 4,987 In accordance with Listing Rule 9.6.2, copies of resolutions passed at the Meeting concerning items other than ordinary business will shortly be available for inspection on the National Storage Mechanism, which can be accessed at . The full text of the resolutions considered at the AGM are contained in the Notice of AGM, published on 25 April 2023, which is available on Arix investor relations . [ENDS] Enquiries For more information on Arix, please contact: Arix Bioscience plc [phone] [e-mail] Powerscourt Group Sarah MacLeod, Ibrahim Khalil, Nick Johnson [phone] [e-mail] About Arix Bioscience plc Arix Bioscience plc is a transatlantic venture capital company focused on investing in breakthrough biotechnology companies around cutting-edge advances in life sciences. We collaborate with exceptional entrepreneurs and provide the capital, expertise, and networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement.

ISIN:	GB00BD045071
Category Code:	RAG
TIDM:	ARIX
LEI Code:	213800OVT3AHQCXNIX43
OAM Categories:	3.1. Additional regulated information required to be disclosed under the laws of a Member State
Sequence No.:	245804
EQS News ID:	1639935

End of Announcement	EQS News Service